- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study2018 | First Faculty of Medicine
- Commentary to study2016 | Second Faculty of Medicine
- The position of SGLT2 inhibitors in current medical practice - update 20222022 | First Faculty of Medicine
- The position of SGLT2 inhibitors in current medicine2020 | First Faculty of Medicine
- Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress2021 | First Faculty of Medicine
- Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension2021 | Third Faculty of Medicine
- The renoprotective effects of canagliflozin demonstrated in the CREDENCE study cannot yet be considered as an effect of the whole class of SGLT2 inhibitors2020 | Second Faculty of Medicine
- Complex effects of gliflozins on cardiovascular systém of diabetic patients2016 | First Faculty of Medicine
- Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial2022 | First Faculty of Medicine
- New treatment options for chronic kidney disease - focused on SGLT2 inhibitors2021 | First Faculty of Medicine
- Renal-protective potential of new oral antidiabetics2015 | Third Faculty of Medicine
- SGLT-2 inhibition a useful tool in the treatment of heart failure with reduced and preserved ejection fraction2022 | Third Faculty of Medicine
- Agonization of GLP-1 in cardiology2020 | Faculty of Medicine in Pilsen
- New possibilities in treatment of type 2 diabetes2012 | Second Faculty of Medicine
- The advantages of fixed combinations of antidiabetics in patients with poor adherence to treatment2018 | First Faculty of Medicine
- Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group2016 | First Faculty of Medicine
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin2021 | Publication without faculty affiliation